We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

55 hedge funds and large institutions have $11.6M invested in Cardiff Oncology in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 7

8% more capital invested

Capital invested by funds: $10.7M → $11.6M (+$901K)

1.45% less ownership

Funds ownership: 17.23% → 15.78% (-1.5%)

8% less funds holding

Funds holding: 60 → 55 (-5)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

85% less call options, than puts

Call options by funds: $37K | Put options by funds: $251K

Holders
55
Holders Change
-5
Holders Change %
-8.33%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
16
Reduced
7
Closed
9
Calls
$37K
Puts
$251K
Net Calls
-$214K
Net Calls Change
-$144K

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$1.12M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$370K
3
Bank of America
Bank of America
North Carolina
+$81.2K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$71.2K
5
Group One Trading
Group One Trading
Illinois
+$38K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$1.05M
2
Deutsche Bank
Deutsche Bank
Germany
-$314K
3
Renaissance Technologies
Renaissance Technologies
New York
-$274K
4
Mercer Global Advisors
Mercer Global Advisors
Colorado
-$207K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$138K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
26
Atom Investors
Texas
$30.2K – – –
DWM
27
Denver Wealth Management
Colorado
$30.1K +$31.3K +18,235 New
Charles Schwab
28
Charles Schwab
California
$27.1K – – –
FWS
29
FinDec Wealth Services
California
$26.4K – – –
UBS Group
30
UBS Group
Switzerland
$25.9K +$17.2K +10,005 +176%
HighTower Advisors
31
HighTower Advisors
Illinois
$25K – – –
TIM
32
Tortoise Investment Management
New York
$24.8K – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$23.7K – – –
GIA
34
Gladstone Institutional Advisory
Florida
$23.1K – – –
CC
35
Callan Capital
California
$22.4K – – –
BAM
36
Belpointe Asset Management
Nevada
$18.9K +$7.65K +4,454 +64%
Wells Fargo
37
Wells Fargo
California
$12.8K +$10.5K +6,104 +363%
Fidelity Investments
38
Fidelity Investments
Massachusetts
$12.1K +$9.96K +5,799 +375%
Citadel Advisors
39
Citadel Advisors
Florida
$11.6K +$2.22K +1,291 +23%
AFIA
40
America First Investment Advisors
Nebraska
$6.6K – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$2.58K +$488 +284 +22%
PNC Financial Services Group
42
PNC Financial Services Group
Pennsylvania
$2.51K +$893 +520 +52%
TRCT
43
Tower Research Capital (TRC)
New York
$1K +$124 +72 +23%
Carson Wealth (CWM LLC)
44
Carson Wealth (CWM LLC)
Nebraska
$1K +$1.46K +850 New
GRP
45
Global Retirement Partners
California
$651 – – –
EBA
46
Eagle Bay Advisors
New York
$559 – – –
LFG
47
Larson Financial Group
Missouri
$248 – – –
NC
48
NewSquare Capital
Pennsylvania
$206 – – –
NFSG
49
Newbridge Financial Services Group
Florida
$190 – – –
US Bancorp
50
US Bancorp
Minnesota
$180 – – –
1
2
3

CRDF Hedge Fund Activity: Q1 2023 in Review

55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2023, worth a combined $11.6M — up 8.4% from $10.7M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CRDF and 5 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 16 added.

The largest buyer was Citigroup, adding an estimated $1.12M. The largest seller was Artal Group, exiting entirely with an estimated $1.05M sold.

  • 55 institutional investors held Cardiff Oncology (CRDF) as of Q1 2023, down from 60 in Q4 2022.
  • Funds reported $11.6M of Cardiff Oncology stock for Q1 2023, up 8.4% quarter-over-quarter.
  • 5 funds opened new Cardiff Oncology positions in Q1 2023 and 9 closed out, a net change of -4 holders.
  • The largest Cardiff Oncology buyer in Q1 2023 was Citigroup, an estimated $1.12M added.
  • The largest Cardiff Oncology seller in Q1 2023 was Artal Group, an estimated $1.05M sold.

Based on aggregated 13F filings for Q1 2023.